AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23313603 — intervention group
Group type: EXPERIMENTAL
Intervention: High and low valence
Number of subjects: 121
Study 23313603 — intervention group
Group type: EXPERIMENTAL
Intervention: Valence and arousal
Number of subjects: 121
Study 23313603 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN minus CRN difference
Number of subjects: 121
Study 23313603 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-related differences
Number of subjects: 121
Study 22137068 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (target dose 30 mg daily)
Number of subjects: 3515
Study 22137068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 3515
Study 19005996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (Group A)
Number of subjects: 100
Study 19005996 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (Group B)
Number of subjects: 100
Study 19005996 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (Group C)
Number of subjects: 100
Study 17539316 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatis root eyedrops, administered six times each day for 7 days.
Number of subjects: 200
Study 17539316 — intervention group
Group type: COMPARATOR
Intervention: Hailun eyedrops (levofloxacin eyedrops), administered six times each day for 7 days.
Number of subjects: 200
Study 15129409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power ultrasound applied to the trigger points before stretching the muscle
Number of subjects: 72
Study 15129409 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound
Number of subjects: 72
Study 11820329 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 3 cm3)
Number of subjects: 9
Study 11820329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl saline; 3 cm3)
Number of subjects: 9
Study 7921715 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam and exposure
Number of subjects: 154
Study 3073808 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 months' treatment with rifampicin and isoniazid, supplemented by ethambutol for the first 8 weeks
Number of subjects: 73
Study 3073808 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 months' treatment with rifampicin and isoniazid, supplemented by ethambutol for the first 8 weeks
Number of subjects: 73
Study 31832789 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous bolus of cyclosporine
Number of subjects: 969
Study 28934258 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives to improve hypertension care
Number of subjects: 65
Study 25936465 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 42
Study 25936465 — intervention group
Group type: COMPARATOR
Intervention: Sham manual contact
Number of subjects: 42
Study 23938175 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 135
Study 23938175 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 135
Study 21864362 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive Interactive Neurostimulation (NIN) therapy using the InterX device, 8 sessions over 3 post-op days
Number of subjects: 61
Study 21864362 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital course of pain medication and rehabilitation
Number of subjects: 61
Study 18556359 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (CE-MRA)
Number of subjects: 52
Study 18556359 — intervention group
Group type: COMPARATOR
Intervention: 3D time-of-flight MR angiography (TOF MRA)
Number of subjects: 52
Study 18556359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CE-MRA and TOF MRA
Number of subjects: 52
Study 16581404 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128)
Number of subjects: 248
Study 16581404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=120)
Number of subjects: 248
Study 12921641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasea (group A, n = 43)
Number of subjects: 85
Study 12921641 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (group B, n = 42)
Number of subjects: 85
Study 11910610 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopause Rating Scale (MRS)
Number of subjects: 306
Study 9415856 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral naloxone
Number of subjects: 30
Study 9415856 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load
Number of subjects: 30
Study 9415856 — intervention group
Group type: EXPERIMENTAL
Intervention: Marlowe‐Crowne Social Desirability Scale (MCSDS)
Number of subjects: 30
Study 7965483 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS solution
Number of subjects: 61
Study 7965483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted ORS solution
Number of subjects: 61
Study 7965483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) therapy
Number of subjects: 61
Study 3109959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation initiated on day 2
Number of subjects: 104
Study 3109959 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation initiated on day 4
Number of subjects: 104
Study 31704268 — intervention group
Group type: EXPERIMENTAL
Intervention: Interocclusal splints postoperatively
Number of subjects: 40
Study 31704268 — intervention group
Group type: COMPARATOR
Intervention: Control group (no splints)
Number of subjects: 40
Study 29402422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 1525
Study 29402422 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only (ASA)
Number of subjects: 1525
Study 29402422 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 1525
Study 29402422 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 1525
Study 27935521 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (5 g leucine/meal)
Number of subjects: 20
Study 27935521 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 26333227 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Yiyang Capsules (Group A)
Number of subjects: 135
Study 26333227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levocarnitine (Group B)
Number of subjects: 135
Study 26333227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Shugan Yiyang Capsules and oral levocarnitine (Group C)
Number of subjects: 135
Study 23127584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure at 19:00 or 21:00h
Number of subjects: 27
Study 23127584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 27
Study 22022855 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted multi-component behavioral intervention
Number of subjects: 0
Study 22022855 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched HIV health education and counseling (Control)
Number of subjects: 0
Study 18550333 — intervention group
Group type: EXPERIMENTAL
Intervention: Records request included with a colorectal cancer screening survey (with-survey group)
Number of subjects: 890
Study 18550333 — intervention group
Group type: COMPARATOR
Intervention: Request in a separate mailing following a completed survey (after-survey group)
Number of subjects: 890
Study 16482066 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of NUTRIOSE FB daily
Number of subjects: 48
Study 16482066 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 g of NUTRIOSE FB daily
Number of subjects: 48
Study 16482066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (22.5 g of pure maltodextrin)
Number of subjects: 48
Study 16482066 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE FB (both doses)
Number of subjects: 48
Study 14606984 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 14606984 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (general)
Number of subjects: 0
Study 10759337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 133
Study 10759337 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 133
Study 9363139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic therapy changed to oral therapy after being afebrile for 16 hours, able to take antibiotics by mouth, and leukocyte count returning towards normal.
Number of subjects: 0
Study 9363139 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy with nutritional supplements and vitamin C.
Number of subjects: 0
Study 9363139 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly immunization with influenza A and B virus vaccine.
Number of subjects: 0
Study 8335810 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (5 to 10 mg intravenously followed by 25 to 50 mg orally every 12 h)
Number of subjects: 292
Study 8335810 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (20 to 40 mg intravenously followed by 20 to 40 mg orally every 8 h)
Number of subjects: 292
Study 8335810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 2417784 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (salbutamol)
Number of subjects: 20
Study 2417784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30355202 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4597
Study 30355202 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4597
Study 29450341 — intervention group
Group type: EXPERIMENTAL
Intervention: TD OCT (Stratus)
Number of subjects: 121
Study 29450341 — intervention group
Group type: COMPARATOR
Intervention: SD OCT (Cirrus)
Number of subjects: 121
Study 29450341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical conversion equations
Number of subjects: 121
Study 24645944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 797
Study 24645944 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 797
Study 20153269 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing
Number of subjects: 75
Study 20153269 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Number of subjects: 75
Study 20153269 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP)
Number of subjects: 75
Study 20153269 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating PEP
Number of subjects: 75
Study 20153269 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 18661389 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative life circumstances ads
Number of subjects: 488
Study 18661389 — intervention group
Group type: COMPARATOR
Intervention: Control ads
Number of subjects: 488
Study 18661389 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry manipulation ads
Number of subjects: 488
Study 18661389 — intervention group
Group type: EXPERIMENTAL
Intervention: All ads (including negative life circumstances, control, and industry manipulation)
Number of subjects: 488
Study 15679494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with polyethyleneglycol
Number of subjects: 185
Study 15679494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mechanical bowel preparation)
Number of subjects: 185
Study 12970211 — intervention group
Group type: EXPERIMENTAL
Intervention: Valve Replacement (VR)
Number of subjects: 370
Study 12970211 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of thromboembolism (TE) following AVR
Number of subjects: 370
Study 12970211 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of thromboembolism (TE) following MVR/DVR
Number of subjects: 370
Study 12484313 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8666763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents
Number of subjects: 56
Study 8666763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 1643681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of musculo-cutaneous nerve and one other nerve (G-2)
Number of subjects: 75
Study 1643681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of all four major nerves (G-1)
Number of subjects: 75
Study 1643681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of radial nerve (G-3)
Number of subjects: 75
Study 1643681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of median nerve (G-4)
Number of subjects: 75
Study 1643681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of ulnar nerve (G-5)
Number of subjects: 75
Study 6715723 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized ragweed (PRW)
Number of subjects: 50
Study 6715723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6715723 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 50
Study 31077026 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy intervention (SG)
Number of subjects: 34
Study 31077026 — intervention group
Group type: COMPARATOR
Intervention: No intervention (CG)
Number of subjects: 34
Study 30341114 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention on SNAP (Smoking, Nutrition, Alcohol, and Physical inactivity)
Number of subjects: 824
Study 30341114 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 824
Study 27232978 — intervention group
Group type: EXPERIMENTAL
Intervention: W5″ Test (Five Seconds Power Test)
Number of subjects: 30
Study 27232978 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 30
Study 27232978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24009085 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal warmth at age 5
Number of subjects: 65
Study 24009085 — intervention group
Group type: EXPERIMENTAL
Intervention: High reported maternal warmth and induction
Number of subjects: 65
Study 24009085 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater HPA-axis reactivity at age 7
Number of subjects: 65
Study 24009085 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 5 maternal warmth
Number of subjects: 65
Study 23259209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene foam 0.1%
Number of subjects: 14
Study 23259209 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 14
Study 20484643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU)
Number of subjects: 0
Study 20484643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19078836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic thermometer
Number of subjects: 0
Study 19078836 — intervention group
Group type: COMPARATOR
Intervention: Oral and axillary thermometers
Number of subjects: 0
Study 16536107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 microg (Group F)
Number of subjects: 60
Study 16536107 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.4 ml (Group S)
Number of subjects: 60
Study 12426644 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (3 sessions per week for 3 months)
Number of subjects: 24
Study 12426644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 24
Study 10526804 — intervention group
Group type: EXPERIMENTAL
Intervention: Active forced-air warming of the two upper limbs (Group Upper body, n = 24)
Number of subjects: 48
Study 10526804 — intervention group
Group type: COMPARATOR
Intervention: Active forced-air warming of the unoperated lower limb (Group Lower extremity, n = 24)
Number of subjects: 48
Study 7791060 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren Ophthalmic)
Number of subjects: 200
Study 7791060 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (Ocufen)
Number of subjects: 200
Study 7791060 — intervention group
Group type: COMPARATOR
Intervention: Incision size (5.2 mm versus 7.0 mm)
Number of subjects: 200
Study 7791060 — intervention group
Group type: COMPARATOR
Intervention: Intraocular carbachol (Miostat)
Number of subjects: 200
Study 2028533 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of metoprolol
Number of subjects: 1153
Study 2028533 — intervention group
Group type: COMPARATOR
Intervention: Single daily dose of metoprolol plus a single dose of placebo
Number of subjects: 1153
Study 6689389 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg
Number of subjects: 0
Study 6689389 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 3 X 20 mg
Number of subjects: 0
Study 6689389 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 3 X 60 mg
Number of subjects: 0
Study 6689389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 3 X 20 mg
Number of subjects: 0
Study 6689389 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of Isosorbide dinitrate (ISDN)
Number of subjects: 0
Study 29741962 — intervention group
Group type: EXPERIMENTAL
Intervention: MSWDQ‐23
Number of subjects: 124
Study 28727540 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation by a community health worker for CRC screening (PN)
Number of subjects: 731
Study 28727540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PLUS)
Number of subjects: 731
Study 28727540 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing for blood pressure control by a trained counselor (MINT)
Number of subjects: 731
Study 25899119 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle meatal silastic stent
Number of subjects: 36
Study 25899119 — intervention group
Group type: COMPARATOR
Intervention: Control (no stent)
Number of subjects: 36
Study 24385406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl (SLF)
Number of subjects: 40
Study 24385406 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine (OM)
Number of subjects: 40
Study 23016517 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel at 20 mg/m(2)
Number of subjects: 18
Study 23016517 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel at 10 mg/m(2) and 15 mg/m(2)
Number of subjects: 18
Study 23016517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intensity-modulated radiation therapy (IMRT) at 78 Gy
Number of subjects: 18
Study 23016517 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (ADT)
Number of subjects: 18
Study 19147446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 30
Study 19147446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with atrial overdrive pacing (CRT + AOP)
Number of subjects: 30
Study 17540811 — intervention group
Group type: EXPERIMENTAL
Intervention: Global endometrial ablation (thermal balloon ablation technology or bipolar radiofrequency ablation technology)
Number of subjects: 41
Study 15130569 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation acupoint stimulation followed by acupressure with lavender oil (8 sessions over 3 weeks)
Number of subjects: 0
Study 15130569 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 11207153 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered coffee consumption
Number of subjects: 14
Study 11207153 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered coffee consumption
Number of subjects: 14
Study 11207153 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated or boiled coffee consumption
Number of subjects: 14
Study 11207153 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 9701432 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg x puff(‐1)) with end-inspiratory pause (EIP) of 5 s
Number of subjects: 12
Study 9701432 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 microg x puff(‐1)) without end-inspiratory pause (EIP)
Number of subjects: 12
Study 7974337 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative measurements of Prothrombin Fragment 1 + 2 (F1 + 2)
Number of subjects: 40
Study 7974337 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative measurements of Thrombin‐antithrombin III complex (TAT)
Number of subjects: 40
Study 7974337 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative measurements of Fibrinopeptide A (FpA)
Number of subjects: 40
Study 7974337 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative measurements of Fibrin and Fibrinogen Degradation Products (FbDP)
Number of subjects: 40
Study 7974337 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative measurements of Soluble Fibrin (SF)
Number of subjects: 40
Study 7974337 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative measurements of Fibrinogen Degradation Products (FgDP)
Number of subjects: 40
Study 2684804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g olsalazine
Number of subjects: 105
Study 2684804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 769630 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic acupuncture
Number of subjects: 42
Study 769630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (needles did not penetrate the skin)
Number of subjects: 42
Study 31358702 — intervention group
Group type: COMPARATOR
Intervention: Single session of transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 94
Study 31358702 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily transcutaneous vagus nerve stimulation (tVNS) for two weeks
Number of subjects: 94
Study 28806904 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls prevention programme based on the Otago Exercise Programme, lasting 12 weeks including home visits and motivational telephone calls.
Number of subjects: 150